Neurocrine Biosciences Inc (NBIX)
117.44
-5.44
(-4.42%)
USD |
NASDAQ |
Nov 15, 16:00
117.22
-0.22
(-0.19%)
After-Hours: 20:00
Neurocrine Biosciences Free Cash Flow (Quarterly): 149.90M for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 149.90M |
| June 30, 2024 | 53.00M |
| March 31, 2024 | 119.10M |
| December 31, 2023 | 118.10M |
| September 30, 2023 | 204.40M |
| June 30, 2023 | 172.80M |
| March 31, 2023 | -133.70M |
| December 31, 2022 | 141.20M |
| September 30, 2022 | 100.50M |
| June 30, 2022 | 129.30M |
| March 31, 2022 | -48.10M |
| December 31, 2021 | -4.70M |
| September 30, 2021 | 56.10M |
| June 30, 2021 | 98.90M |
| March 31, 2021 | 82.80M |
| December 31, 2020 | 90.00M |
| September 30, 2020 | -20.80M |
| June 30, 2020 | 114.20M |
| March 31, 2020 | 34.20M |
| December 31, 2019 | 94.70M |
| September 30, 2019 | 94.30M |
| June 30, 2019 | 59.70M |
| March 31, 2019 | -116.40M |
| December 31, 2018 | 44.49M |
| September 30, 2018 | 56.56M |
| Date | Value |
|---|---|
| June 30, 2018 | 15.84M |
| March 31, 2018 | -40.29M |
| December 31, 2017 | 38.20M |
| September 30, 2017 | -12.11M |
| June 30, 2017 | -48.64M |
| March 31, 2017 | -78.72M |
| December 31, 2016 | -31.97M |
| September 30, 2016 | -31.79M |
| June 30, 2016 | -16.58M |
| March 31, 2016 | -29.95M |
| December 31, 2015 | -16.03M |
| September 30, 2015 | -18.89M |
| June 30, 2015 | 13.45M |
| March 31, 2015 | -18.46M |
| December 31, 2014 | -15.75M |
| September 30, 2014 | -12.37M |
| June 30, 2014 | -10.61M |
| March 31, 2014 | -10.02M |
| December 31, 2013 | -11.07M |
| September 30, 2013 | -10.81M |
| June 30, 2013 | -10.12M |
| March 31, 2013 | 1.853M |
| December 31, 2012 | -8.951M |
| September 30, 2012 | -8.61M |
| June 30, 2012 | -7.096M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-133.70M
Minimum
Mar 2023
204.40M
Maximum
Sep 2023
77.60M
Average
96.80M
Median
Free Cash Flow (Quarterly) Benchmarks
| Repligen Corp | 34.79M |
| West Pharmaceutical Services Inc | 98.80M |
| Bruker Corp | 5.80M |
| The Cooper Companies Inc | 118.50M |
| Integra Lifesciences Holdings Corp | -7.161M |